The transaction was announced on September 29, 2014 and included upfront consideration of $600 million in cash and 3,209,971 shares of AMAG common stock, and additional contingent consideration of up to $350 million based on the …
... to undertake an ill-conceived business plan that has resulted in an approximate 80% decrease in the value of …
the Board of Directors of AMAG approved awards to Ms. Berns of (i) an option to purchase 20,000 shares of common stock and (ii) 9,000 restricted stock units. The option will have an exercise price equal to the closing price of AMAG's …
Upon conversion, holders of the notes will receive shares of AMAG's common stock, cash or a combination thereof, at …
Still, news of Amag’s biggest deal ever and Chief Executive William Heiden’s assertion to hunt for growth through acquisitions failed to move shareholders. The stock was flat in morning trading. Cord Blood Registry (CBR), owned by …
A small activist hedge fund known for pushing for change at troubled small-cap companies is taking aim at AMAG Pharmaceuticals (AMAG), a test ... company to use its cash to buy back its depressed stock. AMAG shares have …
... pay Endoceutics $50 million of total upfront consideration and issue Endoceutics 600,000 unregistered shares of AMAG common stock. Further, AMAG will pay Endoceutics up to $10 million upon delivery of adequate launch quantities of …
BOSTON (MarketWatch) -- AMAG Pharmaceuticals Inc. shares fell in afternoon trading ... Leerink reduced their price target for the stock to $40 from $45, but maintained their outperform rating. Analysts at Robert W. Baird, meanwhile, …
June 9, 2015 (GLOBE NEWSWIRE) -- AMAG Pharmaceuticals, Inc. (Nasdaq:AMAG) today announced the appointment …